Novamind reports rising revenues and cash on hand of CAD$10 million.
What Field Trip’s Huge Financing Tells Investors
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.
Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
MINDCURE's new Director is a veteran of capital markets.
Proposed California Psychedelics Bill Would Be Sector Turning Point
California's new proposed psychedelics "decriminalization" would, in fact, LEGALIZE possession of many psychedelic substances.
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first line of mushroom-based nootropics now available for sale.
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
U.S. Psychedelic Drug Legalization: Urgency or Inertia?
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
New 5-Year Psychedelics Warrants Offer Exciting Leverage Play
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
